	US 12,121,596 B2
	Near infrared fluorescent dyes, formulations and related methods
Samuel Achilefu, St. Louis, MO (US); Rui Tang, St. Louis, MO (US); Duanwen Shen, St. Louis, MO (US); Avik Som, St. Louis, MO (US); Baogang Xu, St. Louis, MO (US); Gail Sudlow, St. Louis, MO (US); Christopher Egbulefu, St. Louis, MO (US); Partha Karmakar, St. Louis, MO (US); and Kexian Liang, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Jun. 1, 2023, as Appl. No. 18/327,455.
Application 18/327,455 is a continuation of application No. 17/119,305, filed on Dec. 11, 2020, granted, now 11,712,482.
Claims priority of provisional application 62/976,702, filed on Feb. 14, 2020.
Claims priority of provisional application 62/947,974, filed on Dec. 13, 2019.
Prior Publication US 2023/0321283 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 49/00 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/42 (2017.01); A61P 35/00 (2006.01); C09B 69/10 (2006.01)

CPC A61K 49/0034 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 47/42 (2013.01); A61K 49/0056 (2013.01); A61K 49/0089 (2013.01); A61P 35/00 (2018.01); C09B 69/105 (2013.01)]

37 Claims

1. A pharmaceutical composition comprising an effective amount of a compound chosen from cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301), cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Tyr-OH (LS838) and a pharmaceutically acceptable salt thereof, wherein each amino acid residue is independently in a D or L configuration; a divalent metal ion; and a pharmaceutically acceptable carrier.